Surgical and catheter-based cardiovascular procedures and adjunctive pharmacology have an inherent risk of neurological complications. The current diversity of neurological endpoint definitions and ascertainment methods in clinical trials has led to uncertainties in the neurological risk attributable to cardiovascular procedures and inconsistent evaluation of therapies intended to prevent or mitigate neurological injury. Benefit-risk assessment of such procedures should be on the basis of an evaluation of well-defined neurological outcomes that are ascertained with consistent methods and capture the full spectrum of neurovascular injury and its clinical effect. The Neurologic Academic Research Consortium is an international collaboration intended to establish consensus on the definition, classification, and assessment of neurological endpoints applicable to clinical trials of a broad range of cardiovascular interventions. Systematic application of the proposed definitions and assessments will improve our ability to evaluate the risks of cardiovascular procedures and the safety and effectiveness of preventive therapies.
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Introduction
Stroke is among the most feared complications of surgical and transcatheter cardiovascular interventions, affecting both benefit-risk evaluations and health care costs. [1] [2] [3] [4] [5] [6] The primary mechanism of procedure-related stroke is focal or multifocal embolization during cardiovascular instrumentation or surgical manipulation; diffuse cerebral hypoperfusion from sustained or profound procedural hypotension (i.e., global hypoxic ischemic injury) is a less common cause. The ongoing risk of spontaneous stroke beyond the periprocedural time frame may be more dependent on patient-related risk factors, although late device-related complications are also a concern. 7, 8 Clinical manifestations of periprocedural stroke are highly variable and substantially underreported, and systematic evaluations by neurologists commonly uncover more subtle, but nonetheless clinically significant, neurological deficits. 6, [9] [10] [11] [12] Routine neuroimaging has revealed that "silent" ischemic cerebral infarcts are common after a wide range of procedures, 9, 13 although their clinical significance and association with subsequent cognitive decline and future stroke remains incompletely characterized. 14, 15 Because such infarcts are estimated to affect 600,000 patients annually in the United States alone, 16 a better understanding of their clinical implications, and the role of imaging and cognitive measures in device and procedural evaluations, is necessary. The Neurologic Academic Research Consortium (NeuroARC) is an international collaboration convened to propose sensitive but pragmatic definitions and assessments for neurological injury relevant to cardiovascular interventions.
NeuroARC Composition and Goals
In accordance with the Academic Research Consortium mission statement 17 , we convened diverse stakeholders, including physician and scientific leaders in interventional and structural cardiology, electrophysiology, cardiac surgery, neurology, neuroradiology, and neuropsychology; clinical trialists representing academic research organizations from the United States and Europe; and representatives from the U.S. Food and Drug Administration and the medical device industry (Online Appendix). Inperson meetings were held on October 11, 2015, in San Francisco, California, and on January 30, 2016, in New York, New York. Following the initial meeting, writing groups were established to capture the consensus on specific topics. The resulting draft was presented to and refined by the entire group at the second meeting, and the final document was subsequently adopted by general agreement. The accompanying Online Appendix provides additional details and practical considerations for the implementation of these recommendations in clinical trials.
The goals of NeuroARC are to establish consensus on: 1) definitions for reproducible endpoints reflecting neurological and cognitive outcomes relevant to a range of cardiovascular procedures; 2) classification of neurological events (type, acute severity, timing, and associated long-term disability); and 3) ascertainment methods for consistent event identification, adjudication, and reporting. Basic principles included: 1) emphasis on definitions that reflect clinically meaningful patient outcomes; 2) classification of the full spectrum of neurovascular injury, while discriminating between degrees of clinical effect; and 3) identification of practical assessment methodologies, while maintaining consistency with prior initiatives defining neurological endpoints. [18] [19] [20] NeuroARC endorses incorporating the proposed definitions into the National Institute of Neurological Disorders and Stroke Common Data Element project 21 to increase data quality and to enable pooling of data across trials to enhance scientific, clinical, and regulatory insights.
Scope and challenges of neurological endpoint standardization
The NeuroARC recommendations apply to trials of a range of surgical and catheter-based cardiovascular interventions (and adjunctive pharmacotherapies) involving the heart, ascending aorta, and great vessels, or requiring the use of temporary or long-term mechanical circulatory or cardiopulmonary support (including cardiopulmonary bypass), for which neurological benefits and risks are important considerations. Given the diversity of relevant interventions and devices, these recommendations should be viewed as a framework to inform the application of relevant endpoints and assessments, rather than a mandate for the design of specific trials. NeuroARC recommendations are not intended to address acute stroke interventions, which have distinct therapeutic considerations. Our ability to interpret the risks associated with procedure-related neurovascular injury is challenged by existing gaps in clinical evidence; in particular, the lack of a conclusive link between acute procedurerelated subclinical brain lesions and long-term neurological or cognitive outcomes. We use the term covert central nervous system (CNS) infarction to acknowledge that these events are not necessarily free of clinical consequences, and that detection of neurological or cognitive sequelae is heavily dependent on the nature, sensitivity, and timing of outcome assessments. Because diffusion-weighted imaging (DWI) magnetic resonance imaging brain lesions are frequent after cardiovascular procedures and represent mostly permanent brain damage, and because large populationbased studies demonstrate associations with cognitive decline, clinical stroke, and mortality, 15, 22, 23 NeuroARC aims to define the full spectrum of neurovascular injury with the assumption that standardized data acquisition will accelerate differentiation between clinically meaningful and incidental findings. With these challenges in mind, the NeuroARC consensus is intended to be a living document, and will be reviewed every 2 years to determine whether evolving evidence warrants revision. 
Definition and classification of neurological injury
Brain injury related to cardiovascular procedures spans a spectrum from overt stroke to covert injury, and can be classified according to clinical signs and symptoms and neuroimaging. NeuroARC recommends classification on the basis of symptoms and evidence of CNS injury, including overt (acutely symptomatic) CNS injury (Type 1), covert (acutely asymptomatic) CNS injury (Type 2), and neurological dysfunction (acutely symptomatic) without CNS injury (Type 3). Table 1 summarizes the proposed NeuroARC definition and classification of neurovascular events.
CNS infarction and the role of imaging
With advances in neuroimaging and the widespread availability of magnetic resonance imaging (MRI), the accepted definitions of stroke and transient ischemic attack (TIA) have evolved considerably, shifting toward tissue-based, rather than symptom-based criteria.
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The American Heart Association/American Stroke Association recently proposed a new framework to define stroke that emphasizes CNS infarction, defined as "brain, spinal cord, or retinal cell death attributable to focal arterial ischemia, based on: 1) pathological, neuroimaging, or other objective evidence of cerebral, spinal cord, or retinal focal ischemic injury in a defined vascular distribution; or 2) clinical evidence of cerebral, spinal cord, or retinal focal ischemic injury in a defined vascular distribution with symptoms persisting > _24 hours or until death, and other etiologies excluded". 20 Thus, CNS infarction may be identified by neuroimaging alone, and its effect may be further characterized by the associated neurological and cognitive symptoms and by disability. NeuroARC recommends an approach that maintains historical consistency with the wellestablished symptom-based definitions of stroke, while enhancing the reporting of cerebral injury with the more sensitive tissue-based diagnostic criteria (Table 1, Figure 1 ).
Stroke versus global hypoxicischemic injury
Stroke is the acute onset of symptoms consistent with focal or multifocal CNS injury caused by vascular blockage resulting in ischemia or vascular rupture resulting in hemorrhage, and is distinct from global hypoxic-ischemic injury. Stroke may be widespread, although it always occurs in specific vascular territories, whereas global hypoxicischemic insult causes diffuse neuronal injury that does not respect arterial or venous boundaries, and is often most severe in the more metabolically active grey matter (including the basal ganglia, thalamus, cerebral cortex, cerebellum, and hippocampus). 25 Although ischemic stroke and hypoxic-ischemic injury are not mutually exclusive and may co-occur, the prognoses of stroke and global ischemic injury are wholly distinct: mortality rates are <13% with ischemic stroke 26 compared with up to 80% following severe global hypoxic-ischemic injury. 27 The distinction between focal or multifocal stroke and global hypoxic-ischemic injury is critical in cardiovascular clinical trials where procedural factors (prolonged hypotension or hypoxemia) may occur, or where "showers" of multifocal emboli may mimic global injury. Devices and procedures designed to prevent embolic complications (e.g., neuroprotection devices) can only be expected to have a beneficial effect on focal or multifocal ischemic injury. Therefore, NeuroARC recommends separate reporting of stroke and global hypoxicischemic injury. Although multifactorial, delirium (global neurological dysfunction) without CNS injury should also be adjudicated and reported due to its prognostic implications.
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Cerebral hemorrhage CNS bleeding varies from clinically silent microbleeds to catastrophic hemorrhages, and requires clear definition, classification, and reporting in the context of cardiovascular trials (in which the use of adjunctive anticoagulant and antiplatelet therapy is common). CNS hemorrhage should be classified as a stroke when it is not caused by trauma, is associated with rapidly developing neurological signs or symptoms, and has been confirmed by imaging; major types include intracerebral hemorrhage and subarachnoid hemorrhage. For hemorrhagic conversion of an infarct, NeuroARC recommends a simplified American Stroke Association classification on the basis of the presence or absence of space-occupying effect. 20 Class A hemorrhagic conversions of ischemic stroke or covert infarction represent minor isolated or confluent petechiae without mass effect; Class B hemorrhagic conversions are more significant confluent bleeds or hematomas resulting in mass effect ( Table 1) . In contrast to the American Heart Association/American Stroke Association, NeuroARC proposes to classify both Class A and B bleeds within ischemic stroke ("ischemic stroke with hemorrhagic conversion") or covert infarction ("covert infarction with hemorrhagic conversion") on the basis of presentation, as the goal is to identify the primary mechanism of injury.
Overview of neurological injury assessment in clinical trials
Assessment methodology by device or procedure category
Given the diversity of cardiovascular interventions, a single approach to neurological injury assessment for every type of clinical investigation is impossible. We propose a framework to categorize applicable procedures and devices in Table 2 , and suggest corresponding assessments. Category I includes cardiovascular procedures associated with a risk of acute or long-term neurological events, for which neurological outcomes are primarily a safety measure (e.g., surgical aortic valve replacement, transcatheter aortic valve replacement, or coronary artery bypass graft). Category II consists of devices or therapies intended to reduce the risk of procedure-related stroke, for which neurological outcomes are primarily a measure of effectiveness (e.g., embolic protection devices or adjunctive neuroprotective medications). Finally, Category III includes devices or procedures associated with a procedural stroke risk, but performed specifically to reduce the long-term risk of stroke; these studies are concerned with neurological outcomes as both safety and effectiveness measures (e.g., patent foramen ovale closure, left atrial appendage closure, or carotid artery revascularization). 
Diagnostic algorithms for appropriate incorporation of imaging
diagnostic algorithms for appropriate incorporation of imaging.Unlike spontaneous stroke detection driven by clinical symptoms, trials evaluating neuroprotection devices or adjunctive medications (Category II) require protocol-driven post-procedure neuroimaging ( Figure 1 ) to increase sensitivity for CNS infarction, and therefore, the power of the study to detect a treatment effect. The clinical relevance of a treatment effect driven by subclinical events is subject to interpretation in the context of the totality of trial data (including nonstroke complications) and evolving evidence on the clinical implications of covert CNS infarction. For studies not specifically focusing on perioperative neuroprotection, acquisition of brain imaging should be required in all patients with neurological signs or symptoms or acute delirium that might indicate a neurological event.
Timing of assessments
Serial assessments should be performed in all patients within prespecified timeframes to add consistency to results and provide documentation not only of the timing of injury, but also of reversibility or progression over time ( Figure 2) . Clinical events most often occur in the periprocedural period, and decrease with time. 9 Therefore, neurological and delirium assessments should be performed early (1, 3, and 7 days postprocedure or pre-discharge) and trigger brain imaging and neurological evaluation, as necessary. Because the effects of neurological events may change over time, we recommend neurological screening and disability and quality-of-life assessments at 30 to 90 days in all studies, with longer-term follow-up on the basis of trial design. 30 Disability with modified Rankin Scale (mRS) should always be assessed 90 ± 14 days after any stroke event (rather than after enrollment).
Clinical assessment for stroke and neurological dysfunction
Post-procedural neurological assessment and stroke severity determination eurovascular event rates vary substantially, depending on whether outcomes are ascertained passively or actively (using standardized assessments at prespecified time points). 9, 31 Active stroke detection in the perioperative period can be confounded by recent exposure to anesthesia, patient discomfort, analgesic medications, ventilatory support, and various post-procedural complications. In this context, delirium is the presenting symptom of acute stroke in 13% to 48% of patients, and is associated with worse outcomes and higher mortality. 32 For this reason, new neurological changes or delirium should trigger neuroimaging in all categories of cardiovascular trials. Table 3 includes recommendations for the classification of acute stroke severity and timing in relation to the index procedure. Although the procedure-related risk window may vary by procedure, within 30 days is a generally accepted timeframe to attribute complications to the procedure. Serial assessment of neurological change using established instruments, such as the National Institutes of Health Stroke Scale, and of delirium, using the Confusion Assessment Methods (3-min diagnostic or intensive care unit), are recommended to add consistency to study results, both within and across trials (Online Appendix).
Long-term stroke ascertainment and disability determination
For long-term stroke screening, NeuroARC recommends the use of standardized instruments, including the National Institutes of Health Stroke Scale, as well as validated structured interviews querying for interval stroke symptoms, such as the Questionnaire for Verifying Stroke-Free Status 33 or the ACAS (Asymptomatic Carotid Atherosclerosis Study) transient ischemic attack/stroke algorithm. 34 A patient response indicating a potential stroke symptom should trigger neuroimaging and a formal neurological assessment. Functional impairment and disability from stroke can be reliably assessed using validated tools, such as the mRS. 35 For cardiovascular procedures, it is important to distinguish "fatal" from "disabling" and "nondisabling" strokes, as well as to identify patients having "stroke with complete recovery" (defined in Table 3 ). An important caveat is that the mRS does not formally differentiate between disability due to neurological symptoms and other comorbidities that may influence dependence (such as activity-limiting angina, dyspnea, or orthopedic conditions). Additional disability and quality of life scales are detailed in the Online Appendix.
MRI for the detection and quantification of CNS infarction
MRI is the imaging modality of choice for detection and quantification of brain ischemia related to cardiovascular procedures and is recommended in trials, even if head computed tomography was obtained. At a minimum, NeuroARC recommends an early postprocedural MRI in efficacy trials (category II), and a MRI should be performed following symptoms suggestive of neurological injury in all trial categories. An independent central core laboratory is recommended to enhance consistency with validated qualitative and quantitative analysis methodologies, standardized acquisition protocols, and site training. Suggested reporting of MRI data is summarized in Table 4 , and the Online Appendix discusses additional considerations for preprocedure and late follow-up MRI assessments and reporting.
DWI: relevance and interpretation
DWI allows detection of ischemic injury from several minutes to days after an ischemic event, and is highly sensitive to acute and subacute ischemic insults when performed within 12 h of symptom onset (sensitivity 0.99). The image contrast in DWI is sensitive to the random motion of water molecules, and becomes hyperintense as cytotoxic edema restricts local water diffusion, representing tissue damage resulting from ischemia. [36] [37] [38] Although the observed diffusion defects may resolve with time, virtually all DWI lesions represent permanent neuronal cell death and signify irreversible brain injury. [39] [40] [41] False negative rates for DWI drop substantially after 35 h, 42 and observed lesion volume is maximal at 5 to 7 days. 43 Because DWI lesions may begin to reverse intensity and/or shift through isointensity between 1 and 3 weeks, longer delays should be avoided. Therefore, 2 to 7 days is the recommended time window for acute or subacute imaging following cardiovascular procedures ( Figure 2) . Because measures of DWI visible lesion volumes may change rapidly over time, consistent timing of image acquisition in randomized trials is essential to avoid systematic bias.
T2-weighted fluid-attenuated inversion recovery and hemorrhage sensitive MRI sequences
T 2 -weighted fluid-attenuated inversion recovery detects nonspecific injury after the acute phase and lesions that remain apparent throughout the chronic phase. Although DWI lesions represent irreversible infarction in 98% of cases, 41 chronic lesion burden cannot be fully predicted from acute DWI lesions, as these may increase or decrease in size, resolve, or remain unchanged. The evolution of acute DWI lesions over time is important to consider, as lesions may reverse while damage remains. 44 Moreover, whereas final T 2 lesion volume is often approximately one-half that of initial DWI, 43 this discrepancy does not necessarily reflect tissue salvage. As post-procedure DWI lesions are often at the threshold of detection, lesions may remain invisible on T 2 , despite existing damage, and some DWI lesions do not cavitate, but collapse entirely, leaving little trace on MRI, despite the loss of tissue. 45 T 1 may be more sensitive to whether infarcts are cavitated in the chronic phase, particularly in the posterior circulation. In Comprehensive cognitive assessment is recommended for studies with neurological outcomes as efficacy endpoints (Categories II and III in Table 2 ), and optional for safety studies (Category I in Table 2 ). MRI = magnetic resonance imaging. 
Assessment of cognitive outcomes Role of cognitive evaluation in cardiovascular clinical trials
Cognitive decline is an important, and potentially disabling consequence of surgical and interventional procedures. Although spontaneous covert CNS infarction has been associated with cognitive decline in long-term population-based studies, 15 generalizability to short-term, procedure-related ischemic injury remains to be proven. Increasing appreciation of the potential cognitive consequences of cardiovascular disease and associated interventions has led to new scrutiny of iatrogenic and patient-specific factors that may influence clinical outcomes 47 and quality of life. 48 Although extended cognitive evaluations are not integral to current neurological event definitions, they have provided valuable information in the context of acquired and developmental conditions. 49, 50 Their sensitivity to subtle decrements in function could prove useful in the evaluation of neuroprotective strategies and neurological outcomes in general. NeuroARC strongly recommends cognitive screening (e.g., Montreal Cognitive Assessment) for all cardiovascular trials, and a comprehensive cognitive assessment strategy for studies with neurological outcomes as efficacy endpoints.
Neuropsychological testing considerations
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